A b s t r a c t
Prostate adenocarcinoma is a biologically diverse disease. Factors associated with a greater risk of metastases, symptoms, and an aggressive clinical course include adenocarcinoma of a higher Gleason score, higher pretreatment serum prostate-specific antigen (PSA) levels, and higher clinical stage. 1 Together, these factors identify patients with adenocarcinoma with an unfavorable prognosis for whom there are a limited number of treatment options.
External beam radiation therapy (RT) combined with brachytherapy is an effective treatment option for prostate adenocarcinoma with an unfavorable prognosis. [2] [3] [4] [5] Accumulating experience has substantiated the efficacy and safety of this radiation combination. Computer-generated dosimetry models using computed tomography and transrectal ultrasonography scans provide precise guides and maps for the optimal distribution of radiation throughout the prostate. Despite the sophistication of these integrated technologies, the factors associated with successful local and biochemical control with radiation are poorly understood. The relationships among prostate gland volume, adenocarcinoma volume, adenocarcinoma grade, and radiation dose have not been studied extensively.
The William Beaumont Hospital Radiation Oncology Department (Royal Oak, MI) initiated and maintained a doseescalating study of external beam radiation combined with high dose rate (HDR) brachytherapy for patients with prostate adenocarcinoma with an unfavorable prognosis. Part of this protocol has been the performance of prostate needle core biopsies approximately 18 months after completion of the RT. These routine post-RT biopsies are a valuable asset because they serve as an intermediary window by means of which dose-response relationships can be evaluated.
We studied clinicopathologic features in 78 patients with prostate adenocarcinoma with an unfavorable prognosis treated with the dose-escalation external beam RT and highdose brachytherapy protocol to identify relationships between prostate adenocarcinoma features, prostate gland volume, and radiation dose.
Materials and Methods

Clinical Data
From January 1991 through December 1999, 160 patients with prostate adenocarcinoma with an unfavorable prognosis were treated with the William Beaumont Hospital Radiation Oncology Department dose-escalating, external beam RT with HDR brachytherapy protocol, and one of us (N.S.G.) conducted a complete review of all of their prostate biopsy specimens. Patients were accepted into the treatment protocol based on any of the following parameters: pretreatment serum PSA level, 10.0 ng/mL or more; Gleason score, 7 or more; or clinical stage T2b or more. 6 RT consisted of irradiation to the pelvis with 10-MV or 18-MV photons to a median dose of 46 Gy in 1.8-to 2.0-Gy fractions using a 4-field technique. 6 Pelvic irradiation was supplemented with ultrasound-guided, transperineal, interstitial iridium 192 HDR implants. The median total dose was 77.6 Gy (range, 70.4-92.5 Gy) (equivalent in 2-Gy fractions assuming tumor alpha/beta = 5). [7] [8] [9] [10] Twenty patients (12.5%) received a total radiation dose of 70. 4 No patients received hormonal therapy before, during, or after radiation until biochemical failure.
The study group consisted of the 78 patients who had protocol-directed post-RT prostate needle biopsies that were obtained a mean of 1.5 years (median, 1.73 years; range, 0.6-4.3 years; SD, 0.28 year) after completion of RT. Three (4%) patients underwent the post-RT biopsy more than 2 years after completion of RT. Two patients (3%) underwent biopsy between 9 months and 1 year after completion of RT. There was no difference in post-RT needle core factors (percentage of cores with adenocarcinoma) between the patients who underwent biopsy within 1 year after completion of RT and those who underwent biopsy at 1.5 years. The patients were strongly encouraged to return for their scheduled 1.5-year post-RT biopsy. However, it was impossible to obtain complete compliance with this request; only 38 (49%) of the patients agreed to undergo a post-RT biopsy that was only for protocol purposes. In addition, the interval between the completion of radiation and biopsy was subject to patient-controlled factors. Serum PSA values did not factor into which individuals underwent post-RT biopsy or the time interval of the biopsy. An attempt was made to have all patients undergo biopsy at 1.5 years after RT.
The following clinical features were recorded: (1) pre-RT serum PSA value (ng/mL); (2) prostate volume (cc), determined at the time of transrectal ultrasound; and (3) total radiation dose (Gy).
Pre-RT Prostate Needle Biopsies
All slides from all pre-RT prostate needle core biopsies were reviewed by one of us (N.S.G.) without knowing the outcome of the patient or the RT dose. The following features from the pre-RT prostate needle core biopsy review were recorded: (1) number of needle core biopsies obtained; (2) length of each needle core, measured with an ocular micrometer; (3) number of needle core biopsy specimens containing adenocarcinoma; (4) length of adenocarcinoma in each needle core, measured with an ocular micrometer; (5) Gleason score; and (6) presence of perineural invasion.
Post-RT Prostate Needle Biopsies
All slides from all post-RT biopsies were reviewed by one of us (N.S.G.) without knowing the outcome of the patient or the RT dose. All post-RT prostate needle core tissue blocks had a cytokeratin 34 beta E12 immunohistochemical stain applied to at least 1 unstained level that was obtained at the time of the initial block sectioning.
The following features from the post-RT prostate needle core biopsy review were recorded: (1) number of needle core biopsy specimens obtained; (2) number of needle core biopsy specimens containing adenocarcinoma; (3) most common radiation effect score (RT effect score) of residual adenocarcinoma, using the system of Crook et al 11 (A detailed description of this scoring system, technical points on its application, and color photographs of adenocarcinoma displaying the different radiation effect scores can be found in a previous study. 12 Briefly, nucleus and cytoplasm radiation changes were scored on a scale of 0 to 3 [most damage] separately and summed for a total score. Scores of 5 or 6 were classified as marked radiation changes, 3 or 4 as moderate radiation changes, and 0 or 2 as none to minimal radiation changes.); (4) least amount RT effect score of residual adenocarcinoma using the aforementioned system (Some residual adenocarcinoma showed marked radiation changes except for a small region in which there was minimal radiation change. A least amount RT effect score was recorded to evaluate whether areas of adenocarcinoma that seemed to receive less radiation were clinically important.); (5) length of each needle core, measured with an ocular micrometer; and (6) length of adenocarcinoma in each needle core, measured with an ocular micrometer.
The association of variables was analyzed using logistic regression or the Fisher exact test (2-tailed) for categoric variables and linear regression for continuous variables. The Student unpaired t test was used to determine the significance of the difference between 2 sample means. A P value of .05 or less was considered statistically significant. Statistical analyses were performed with SYSTAT (version 10.0, SPSS, Chicago, IL).
Background Clinicopathologic Features
The adenocarcinomas were T1c in 4 patients (5%), T2a in 7 patients (9%), T2b in 22 patients (28%), T2c in 32 patients (41%), T3a in 4 patients (5%), T3b in 2 patients (3%), and T3c in 7 patients (9%) ❚Table 1❚. The adenocarcinomas were Gleason score 6 in 34 patients (44%), score 7 in 26 patients (33%), score 8 in 5 patients (6%), and score 9 in 13 patients (17%).
The RT dose was a reflection of the time at which the patient was recruited into the dose-escalating trial. It was not related to the adenocarcinoma Gleason score, serum PSA level, or percentage of needle cores with adenocarcinoma. The mean and median values of these factors were similar among the different RT dose groups ❚Table 2❚.
Results
Residual Post-RT Adenocarcinoma
Seventy-eight patients had post-RT needle core biopsies. Pre-RT features between patients with and without residual post-RT adenocarcinoma are listed in ❚Table 3❚. Factors that had a significant association with an increasing percentage of needle cores with residual post-RT adenocarcinoma, when analyzed as a univariate continuous variable (linear regression), were lower total RT dose (P = .02), lower dose per implant (P = .03), and greater pre-RT serum PSA value (P = .04) ❚Table 4❚. An increasing percentage of pre-RT needle cores with adenocarcinoma trended toward a significant association (P = .06). Increasing Gleason score (P = .37) and increasing T classification (P = .88) were not significantly related.
Lower total RT dose was the only factor that remained significantly associated with an increasing percentage of needle cores with residual post-RT adenocarcinoma on multivariate analysis (P = .05). Serum PSA level and percentage of pre-RT needle cores with adenocarcinoma did not retain a significant association.
Post-RT Adenocarcinoma RT Effects
Patients with post-RT residual adenocarcinoma most common RT effect scores of 0 to 4 were grouped together for statistical purposes ❚Table 5❚. The mean and median pre-RT Gleason scores were 6.9 and 6 in patients with marked RT effect scores and 7.3 and 7 in patients with RT effect scores of none to moderate, respectively. The mean and median total radiation doses were 77 Gy and 77 Gy in patients with marked RT effect scores and 75.5 Gy and 73.9 Gy in patients with RT effect scores of none to moderate, respectively.
There were no significant differences in the mean pre-RT adenocarcinoma Gleason scores (P = .60), mean total radiation doses (P = .24), composite length of pre-RT adenocarcinoma (P = .69), composite length of pre-RT needle core biopsy specimens (P = .76), and number of needle cores (P = .83) between patients with no post-RT residual adenocarcinoma, patients with marked RT effect scores, and patients with RT effect scores of none to moderate.
Of the 32 post-RT adenocarcinomas from patients who received 70 to 80 Gy, 24 (75%) had RT effect scores of only none to moderate. One adenocarcinoma (3%) displayed a heterogeneous pattern of RT effect. Of the 32 post-RT adenocarcinomas, 7 (22%) had only marked RT effects. The percentage of post-RT adenocarcinomas with marked RT effects increased in patients who received more than 80 Gy.
The percentage of post-RT adenocarcinomas with no to moderate RT effects was greater in the patient group with adenocarcinoma in 34% or more of the pre-RT needle cores. Three (23%) of 13 patients with adenocarcinoma in 33% or less of the pre-RT needle cores had post-RT adenocarcinoma with no to moderate RT effects (most or least common), whereas 10 (34%) of 29 patients with adenocarcinoma in 34% or more of the pre-RT needle cores had post-RT adenocarcinoma with no to moderate RT effects.
Post-RT Adenocarcinoma With No to Moderate RT Effects
The patients were grouped in 2 manners to examine factors related to the presence of residual post-RT adenocarcinoma with RT effect scores of none to minimal.
The first set of analyses was limited to patients with residual post-RT adenocarcinoma ❚Table 6❚. Patients with no residual post-RT adenocarcinoma were excluded. The mean percentage of pre-RT biopsy adenocarcinoma needle cores was 76% among patients with RT effect scores of none to moderate compared with 57% in patients with marked RT effect scores (P = .02). The mean percentage of post-RT biopsy adenocarcinoma needle cores also was significantly larger in the group with RT effect scores of none to moderate than in the group with marked most common RT effect scores (58% vs 39%; P = .01).
Lower RT dose (P = .02), increasing percentage of needle cores with adenocarcinoma (P = .04), and increasing pretreatment serum PSA level (P = .04) were significantly associated with an increasing percentage of needle cores with RT effect scores of none to moderate in this group of patients with post-RT residual adenocarcinoma.
The second set of analyses included all 78 patients with post-RT biopsies. Cases with RT effect scores of none to moderate in the residual post-RT adenocarcinoma were compared with the cases with either no residual post-RT adenocarcinoma or those with marked RT effect scores in residual adenocarcinoma ❚Table 7❚. Patients with RT effect scores of none to moderate in residual post-RT adenocarcinoma had a significantly greater percentage of pre-RT needle cores with adenocarcinoma (mean, 76% vs 53%; P = .02) and perineural invasion (present in 70% vs 33%; P = .04) than patients with no residual or residual adenocarcinoma with marked RT effect scores.
Only an increasing percentage of pre-RT needle cores with adenocarcinoma was associated significantly with an RT, radiation therapy. * Data are given as number (percentage).
increasing percentage of post-RT needle cores with RT effect scores in the adenocarcinoma of none to moderate when it was analyzed as a continuous variable (P = .02) ❚Table 8❚.
Factors that did not achieve statistical significance in any of the analyses were prostate gland volume, composite length of needle cores, and composite length of adenocarcinoma.
Discussion
We studied the relationships among radiation dose, adenocarcinoma features, and prostate gland volume using the dose-escalation nature of the treatment protocol and the pre-RT and post-RT needle core biopsy specimens. Two sets of analyses were performed, pre-RT factors associated with post-RT residual adenocarcinoma and factors associated with residual adenocarcinoma with RT effect scores of none to moderate. Together, they provide corroborative insight into the components of the dose-response relationship of prostate adenocarcinoma with an unfavorable prognosis.
A dose-response relationship seems to be highly operational in this group of prostate adenocarcinoma patients, substantiating previous authors' opinions of its existence. 6, [13] [14] [15] [16] [17] By using the percentage of needle cores with adenocarcinoma and serum PSA level as surrogate markers of adenocarcinoma volume, 18-20 these parameters and serum PSA level and radiation dose affected the presence, percentage of cores with adenocarcinoma, and degree of radiation effect of residual post-RT adenocarcinoma. A larger percentage of pre-RT needle cores with adenocarcinoma, higher serum PSA levels, and lower radiation doses were associated with a larger percentage of post-RT needle cores with adenocarcinoma and the presence and an increasing percentage of needle cores with adenocarcinoma with no to moderate RT effects. The percentage of post-RT adenocarcinomas with marked RT effects increased in patients who received larger radiation doses and who had adenocarcinoma in a smaller percentage of pre-RT needle cores. Last, the mean percentage of needle cores with residual post-RT adenocarcinoma with RT effect scores of none to moderate was significantly larger than the mean percentage of needle cores with residual post-RT adenocarcinoma with marked RT effect scores. Adenocarcinoma volume, using the surrogate marker of percentage of needle cores with adenocarcinoma, and radiation dose seem to be the key components in the doseresponse relationship. Prostate gland volume did not seem to influence this relationship, even when RT dose and gland volume were analyzed together.
The results of this study also provide substantiating evidence to affirmatively answer the question of the importance of adenocarcinoma volume using the surrogate markers of percentage of needle cores with adenocarcinoma and serum PSA level in RT raised by other authors. 18, [21] [22] [23] [24] [25] Additional support for the pivotal role of adenocarcinoma volume in the dose-response relationship can be gleaned from the literature. Increasing radiation dose was associated significantly with a smaller percentage of patients with post-RT adenocarcinoma without typical radiation-induced changes (RT effect scores of none to moderate) and a larger percentage of patients with post-RT adenocarcinoma with radiation changes (marked RT effect scores) in 1 study. 16 The median pre-RT serum PSA value was greater in patients with RT, radiation therapy. * Data are given as mean percentages. © American Society for Clinical Pathology post-RT residual adenocarcinoma with no RT effects than in patients with RT effects (13.1 vs 5.5 ng/mL) in another study. 26 Factors significantly associated with biochemical failure in clinical outcome studies have included composite length of pre-RT adenocarcinoma, adenocarcinoma of higher Gleason score, and higher serum PSA levels. 18,21-25 Gleason score and serum PSA level are each linked closely to the volume of adenocarcinoma in the prostate. [27] [28] [29] In our opinion, adenocarcinoma Gleason score, serum PSA levels, and the composite length of adenocarcinoma in needle cores function as surrogate markers of adenocarcinoma volume in these studies, similar to the surrogate marker of percentage of needle cores with adenocarcinoma volume used in this study. We believe that Gleason score did not show a statistical contribution to the dose-response relationship because it was a statistically weaker surrogate marker of adenocarcinoma volume than percentage of needle cores with adenocarcinoma and serum PSA value. The Gleason score of the pre-RT adenocarcinoma had no statistical vigor in this study. The amount of RT effect in adenocarcinoma cells had no relationship with its pre-RT Gleason score. Similar radiation doses induced a similar range of RT effects in adenocarcinoma cells of intermediate and high Gleason score. This suggests that the presumed radiation sensitivities, or lack thereof, that are thought to be intrinsic to adenocarcinoma cells of increasing Gleason score are an invalid biologic model. The architectural pattern groups of the Gleason scoring system offer no direct insight into whether the neoplastic cells forming those structures can be eradicated or sterilized by radiation.
The radiation dose threshold above which marked radiation effects in adenocarcinoma cells can be produced is unknown. Our study suggests it may be possible to achieve homogeneous, marked radiation injury in adenocarcinoma cells with total radiation doses below 80 Gy (radiobiologically equivalent dose assuming an alpha/beta = 5), provided the adenocarcinoma is of a sufficiently small volume. At the opposite end of the spectrum, there were patients with adenocarcinoma in more than 66% of the pre-RT needle cores who received 92.5 Gy and did not have homogeneous radiation injury in post-RT adenocarcinoma. The RT dose needed to achieve marked RT effects or eradication of adenocarcinoma is probably not narrow and seems to be affected greatly by the volume of adenocarcinoma in the prostate.
The mechanisms underlying the dose-response relationship are unknown. Prostate gland volume did not seem to affect the dose-response relationship of RT with prostate adenocarcinoma, including the presence of residual post-RT adenocarcinoma with RT effects of none to moderate. This was a surprise. We anticipated that larger volume prostates were more likely to have zones of lower radiation effect compared with smaller prostates. Our results suggest that larger adenocarcinoma volume, rather than the prostate gland volume in which it is proliferating, is the underlying factor leading to greater amounts of post-RT residual adenocarcinoma with minimal radiation effects. Hypoxia may be the causative process linking these factors. Microvessel density increases proportionally with increasing Gleason score. [30] [31] [32] However, microvessel density also becomes increasingly irregular with increasing Gleason score. Possibly less well vascularized regions develop within larger volume adenocarcinomas, and the adenocarcinoma cells in the less well vascularized regions are relatively hypoxic compared with the adenocarcinoma in regions with high microvessel density scores. Radiation achieves its tumoricidal effect through the generation of free radicals, which requires oxygen. It is possible that the adenocarcinoma in the regions of relative hypoxia (lower microvessel density scores) is less injured by radiation than adenocarcinoma in regions with less hypoxia. This theory is supported by the findings of a study that identified hypoxic areas in prostate adenocarcinoma compared with normal prostate tissue. 33 Substantial amounts of oxygenation heterogeneity within adenocarcinomas of similar Gleason score were found. Increasing hypoxia also was associated with a higher clinical stage.
It is important to point out the unique aspects of the radiation delivery system used in this dose-escalation trial and its potential influence on the dose-response relationships described herein. The technical aspects of HDR brachytherapy using the interactive real-time dosimetry program developed in this protocol resulted in a minimum dose of RT delivered homogeneously to the entire gland. As a result, there was an objective assessment of adenocarcinoma response to the radiation dose because the RT deposition was relatively consistent from patient to patient. This method may be the optimal delivery system to assess a doseresponse relationship of RT with prostate adenocarcinoma. Unlike 3-dimensional conformal RT or permanent seed implants, treatment setup uncertainties, gland motion, gland distortion, and edema were not problematic with HDR brachytherapy. Variation in the delivered radiation dose was minimal, and did not obscure or cloud the observations of a cause and effect relationship between RT dose and morphologic response of the adenocarcinoma.
This study has several design limitations or issues that should be noted. Our goal was to examine factors pertaining to the dose-response relationship. This is not a clinical study that addresses the clinical efficacy, morbidity, or discussion of treatment issues pertaining to this patient cohort. This study also does not address the clinical usefulness of post-RT biopsies or the significance of residual adenocarcinoma. The post-RT biopsies were obtained according to the study protocol, regardless of the patient's serum PSA values. We also are cognizant that sampling factors greatly influence the detection of adenocarcinoma in needle cores, especially after RT, and that a low percentage of needle core biopsy specimens with adenocarcinoma does not negate the possibility of a high volume of adenocarcinoma in the prostate on a single-patient basis. [34] [35] [36] [37] Our goal was to examine overarching radiationadenocarcinoma relationships rather than prognostic parameters that could be applied to an individual patient. The timing of the post-RT biopsy could influence these results in this regard; however, only 3 (4%) of 78 patients had undergone the post-RT biopsy more than 2 years after completion of RT. The median and mean intervals of the post-RT biopsies were both close to 1.5 years. The initial round of data analyses included the parameters of the percentage of total tissue involved by adenocarcinoma and the largest percentage of adenocarcinoma in a single needle biopsy. These factors had close but slightly less robust associations than the percentage of needle cores with adenocarcinoma. Therefore, they were not included in the final version of the study.
We found significant associations among radiation dose, preradiation adenocarcinoma volume, serum PSA levels, and the volume and appearance of postradiation adenocarcinoma. Together, the analyses provide support for the existence of a dose-response relationship in this group of patients. The volume of adenocarcinoma and radiation dose are the key factors in this relationship.
